AU2017357759A1 - Methods of treating PAH with combinations of ralinepag and other agents - Google Patents

Methods of treating PAH with combinations of ralinepag and other agents Download PDF

Info

Publication number
AU2017357759A1
AU2017357759A1 AU2017357759A AU2017357759A AU2017357759A1 AU 2017357759 A1 AU2017357759 A1 AU 2017357759A1 AU 2017357759 A AU2017357759 A AU 2017357759A AU 2017357759 A AU2017357759 A AU 2017357759A AU 2017357759 A1 AU2017357759 A1 AU 2017357759A1
Authority
AU
Australia
Prior art keywords
ralinepag
elevating agent
dose
amount
daily
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2017357759A
Other languages
English (en)
Inventor
John W. Adams
Dominic P. Behan
Lucie H. CLAPP
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arena Pharmaceuticals Inc
Original Assignee
Arena Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharmaceuticals Inc filed Critical Arena Pharmaceuticals Inc
Publication of AU2017357759A1 publication Critical patent/AU2017357759A1/en
Priority to AU2023263497A priority Critical patent/AU2023263497C1/en
Priority to AU2025283444A priority patent/AU2025283444A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
AU2017357759A 2016-11-10 2017-11-10 Methods of treating PAH with combinations of ralinepag and other agents Abandoned AU2017357759A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2023263497A AU2023263497C1 (en) 2016-11-10 2023-11-09 Methods of treating PAH with combinations of ralinepag and other agents
AU2025283444A AU2025283444A1 (en) 2016-11-10 2025-12-16 Methods of treating PAH with combinations of ralinepag and other agents

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662420515P 2016-11-10 2016-11-10
US62/420,515 2016-11-10
US201762530533P 2017-07-10 2017-07-10
US62/530,533 2017-07-10
PCT/US2017/061116 WO2018089804A1 (en) 2016-11-10 2017-11-10 Methods of treating pah with combinations of ralinepag and other agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023263497A Division AU2023263497C1 (en) 2016-11-10 2023-11-09 Methods of treating PAH with combinations of ralinepag and other agents

Publications (1)

Publication Number Publication Date
AU2017357759A1 true AU2017357759A1 (en) 2019-06-06

Family

ID=60451197

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2017357759A Abandoned AU2017357759A1 (en) 2016-11-10 2017-11-10 Methods of treating PAH with combinations of ralinepag and other agents
AU2023263497A Active AU2023263497C1 (en) 2016-11-10 2023-11-09 Methods of treating PAH with combinations of ralinepag and other agents
AU2025283444A Pending AU2025283444A1 (en) 2016-11-10 2025-12-16 Methods of treating PAH with combinations of ralinepag and other agents

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2023263497A Active AU2023263497C1 (en) 2016-11-10 2023-11-09 Methods of treating PAH with combinations of ralinepag and other agents
AU2025283444A Pending AU2025283444A1 (en) 2016-11-10 2025-12-16 Methods of treating PAH with combinations of ralinepag and other agents

Country Status (11)

Country Link
US (2) US12377067B2 (https=)
EP (2) EP4681708A3 (https=)
JP (3) JP2019533713A (https=)
KR (4) KR20260020212A (https=)
CN (2) CN110691612B (https=)
AU (3) AU2017357759A1 (https=)
CA (1) CA3043283A1 (https=)
ES (1) ES3052035T3 (https=)
IL (2) IL266518B1 (https=)
MA (1) MA46750A (https=)
WO (1) WO2018089804A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20260020212A (ko) 2016-11-10 2026-02-10 아레나 파마슈티칼스, 인크. 라리네팍 및 다른 제제의 조합에 의한 pah의 치료 방법
EP3977985B1 (en) 2017-03-01 2023-09-06 Arena Pharmaceuticals, Inc. Compositions comprising pgi2-receptor agonists and processes for the preparation thereof
WO2019222764A1 (en) * 2018-05-16 2019-11-21 Arena Pharmaceuticals, Inc. Compositions comprising pgi2-receptor agonists and processes for the preparation thereof
CN108721296B (zh) * 2018-07-03 2019-04-05 中国人民解放军总医院 一种化合物在治疗或预防高原病中的用途
CN112638865B (zh) * 2018-09-06 2022-07-26 广东东阳光药业有限公司 药物共晶体及其制备方法
CA3123990A1 (en) * 2018-12-21 2020-06-25 Actelion Pharmaceuticals Ltd Pharmaceutical composition for the treatment of pulmonary arterial hypertension
TW202042818A (zh) * 2019-01-25 2020-12-01 瑞士商艾克泰聯製藥有限公司 用於治療慢性血栓性肺高血壓之醫藥組成物
US20230263807A1 (en) * 2022-02-08 2023-08-24 United Therapeutics Corporation Treprostinil iloprost combination therapy
US12098116B2 (en) 2022-02-15 2024-09-24 United Therapeutics Corporation Crystalline prostacyclin (IP) receptor agonist and uses thereof
US20250282716A1 (en) 2024-03-11 2025-09-11 United Therapeutics Corporation Methods of making ip-receptor agonists
CN121714543A (zh) * 2024-09-23 2026-03-24 上海欣药智能科技有限公司 一种可吸入的含可溶性鸟苷酸环化酶受体激动剂的药物组合物及其用途
US12582629B1 (en) * 2025-10-23 2026-03-24 Innovate Therapeutics Llc Extended-release pharmaceutical compositions of Ralinepag

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2085844A1 (en) 1991-12-27 1993-06-28 Nobuyuki Hamanaka Fused benzeneoxyacetic acid derivatives
GB9908934D0 (en) 1999-04-19 1999-06-16 Rolic Ag Liquid crystalline compounds
US20040048844A1 (en) 1999-10-20 2004-03-11 Bristol-Myers Squibb Pharma Company Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents
WO2002055484A1 (en) 2001-01-12 2002-07-18 Takeda Chemical Industries, Ltd. Biaryl compound, process for producing the same, and agent
WO2003007888A2 (en) 2001-07-20 2003-01-30 Adipogenix, Inc. Fat accumulation-modulating compounds
MXPA04001253A (es) 2001-08-09 2004-06-03 Ono Pharmaceutical Co Derivados de acidos carboxilicos y agente farmaceutico que comprende los mismos como ingrediente activo.
TW200307539A (en) 2002-02-01 2003-12-16 Bristol Myers Squibb Co Cycloalkyl inhibitors of potassium channel function
TWI293715B (en) 2002-10-10 2008-02-21 Sipix Imaging Inc A method for inducing or enhancing the threshold of an electrophoretic display, an electrophoretic fluid and an electrophoretic display
CN101723891A (zh) 2003-02-10 2010-06-09 沃泰克斯药物股份有限公司 通过使n-芳基氨基甲酸酯与卤代杂芳基反应制备n-杂芳基-n-芳基胺的方法和类似方法
GB0325291D0 (en) 2003-10-29 2003-12-03 Pfizer Ltd Novel combination
US20060063930A1 (en) 2004-08-20 2006-03-23 Agoston Gregory E Compositions and methods comprising proteinase activated receptor antagonists
WO2007051255A1 (en) 2005-11-04 2007-05-10 The University Of Sydney Process for the preparation of compounds containing an azacyclic ring system
CN101489544A (zh) 2006-05-09 2009-07-22 海玛奎斯特医药公司 治疗血液病的方法
KR20230085944A (ko) * 2008-03-18 2023-06-14 아레나 파마슈티칼스, 인크. 프로스타시클린 （ｐｇｉ２） 수용체와 관련된 장애의 치료에 유용한 상기 수용체의 조절제
JP5603343B2 (ja) 2008-11-26 2014-10-08 アリーナ ファーマシューティカルズ， インコーポレイテッド 関連する障害を処置するために有用なプロスタサイクリン（ｐｇｉ２）受容体モジュレーターとしてのピラゾリル置換炭酸誘導体
PT2370413E (pt) 2008-12-08 2015-10-23 Arena Pharm Inc Moduladores do recetor da prostaciclina (pgi2) úteis para o tratamento de distúrbios relacionados com o mesmo
EP2480526A1 (en) * 2009-09-23 2012-08-01 Arena Pharmaceuticals, Inc. Crystalline forms and processes for the preparation of pgi2 receptor agonists
US9388154B2 (en) 2011-09-12 2016-07-12 Lund Biotechnology PBC Process for preparing synthetic prostacyclins
AU2013351934B2 (en) * 2012-11-30 2018-03-29 Insmed Incorporated Prostacylin compositions and methods for using the same
WO2016065103A1 (en) * 2014-10-23 2016-04-28 Arena Pharmaceuticals, Inc. Method of treating conditions related to the pgi2 receptor
EP3244968B1 (en) * 2015-01-13 2023-08-30 Vivus LLC Combination therapy for pulmonary hypertension
KR20260020212A (ko) 2016-11-10 2026-02-10 아레나 파마슈티칼스, 인크. 라리네팍 및 다른 제제의 조합에 의한 pah의 치료 방법

Also Published As

Publication number Publication date
ES3052035T3 (en) 2025-12-30
CN110691612A (zh) 2020-01-14
KR20260020212A (ko) 2026-02-10
JP2019533713A (ja) 2019-11-21
KR20200015439A (ko) 2020-02-12
AU2023263497C1 (en) 2026-01-22
EP4681708A3 (en) 2026-03-18
AU2025283444A1 (en) 2026-01-15
CA3043283A1 (en) 2018-05-17
JP2023029865A (ja) 2023-03-07
US20190321328A1 (en) 2019-10-24
EP3538154A1 (en) 2019-09-18
WO2018089804A1 (en) 2018-05-17
US12377067B2 (en) 2025-08-05
MA46750A (fr) 2019-09-18
US20260014114A1 (en) 2026-01-15
IL266518B1 (en) 2026-01-01
CN110691612B (zh) 2024-11-08
KR20230021186A (ko) 2023-02-13
KR20240068077A (ko) 2024-05-17
WO2018089804A9 (en) 2018-06-21
AU2023263497B2 (en) 2025-09-18
CN119367341A (zh) 2025-01-28
IL323354A (en) 2025-11-01
AU2023263497A1 (en) 2023-11-30
JP2025131627A (ja) 2025-09-09
IL266518A (en) 2019-07-31
KR102916884B1 (ko) 2026-01-22
EP3538154B1 (en) 2025-09-03
EP4681708A2 (en) 2026-01-21

Similar Documents

Publication Publication Date Title
US20260014114A1 (en) Method of treating pah with combinations of ralinepag and other agents
O'callaghan et al. Treatment of pulmonary arterial hypertension with targeted therapies
Grassi et al. Lercanidipine in the management of hypertension: an update
US6162802A (en) Synergistic combination therapy using benazepril and amlodipine for the treatment of cardiovascular disorders and compositions therefor
Galiè et al. Emerging medical therapies for pulmonary arterial hypertension
US20080188497A1 (en) Dipyridamole, Acetylsalicylic Acid, and Angiotensin II Antagonist Pharmaceutical Compositions
Siddiqui et al. Ranolazine: a review of its use in chronic stable angina pectoris
Hosoya et al. Protection of the cardiovascular system by imidapril, a versatile angiotensin‐converting enzyme inhibitor
Gojanovic et al. Concomitant calcium entry blockade and inhibition of the renin-angiotensin system: a rational and effective means for treating hypertension
Meier et al. The future of angiotensin II inhibition in cardiovascular medicine
RU2182002C2 (ru) Композиция с фиксированной дозой ингибитора ангиотензин-превращающего фермента и антагониста кальциевых каналов, способ ее изготовления и применение для лечения сердечно-сосудистых заболеваний
US20100249103A1 (en) combination treatment
WO2005011727A1 (en) Combination of an activator of soluble guanylate cyclase and an ace-inhibitor for the treatment of a cardiovascular or metabolic disorder
Conway et al. New horizons in antiarrhythmic therapy: will novel agents overcome current deficits?
Lawall et al. Intermittent administration of nitroglycerin sublingual powder compared with placebo in outpatients with peripheral artery disease: results of a randomised proof of concept study
US20050059660A1 (en) Novel combination
Martres HM74a agonists: will they be the new generation of nicotinic acid?
Koumallos et al. Therapeutic interventions to renin-angiotensin-aldosterone system, and vascular redox state
KR20050018330A (ko) 혈관장애의 치료 및 예방을 위한 디피리다몰,아세틸살리실산 및 안지오텐신 ⅱ 길항제의 용도

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted